Introduction {#sec1}
============

Antibiotic resistance is a growing challenge and a major public health threat worldwide. In particular, *Pseudomonas aeruginosa* (PA) exhibits high rates of resistance to many of the currently available antibiotic therapies.[@bib1], [@bib2] Previous reports have indicated that about 80% of patients with cystic fibrosis (CF) have chronic PA lung infections.[@bib3], [@bib4] New treatment options for these infections are therefore urgently required. Because the formation of a biofilm increases the tolerance of PA to antibacterial drugs,[@bib5], [@bib6], [@bib7] inhibition of the PA quorum-sensing (QS) signaling pathway, which regulates multiple PA virulence factors as well as biofilm formation, has been suggested as a promising target.[@bib2], [@bib8], [@bib9], [@bib10], [@bib11] We are therefore developing a novel class of antivirulence agents, quorum sensing inhibitors (QSIs), with the aim of sensitizing PA biofilms to antibiotic treatment.

For respiratory conditions such as lung infections, targeted delivery of drugs directly to the site of action could provide unique benefits compared to systemic administration. Local delivery to the lung could achieve a higher local concentration at the target site with reduced systemic exposure and risk of adverse events.[@bib12] However, despite the increasing interest in pulmonary delivery over the last few decades, compared to conventional oral dosage forms, the pharmacokinetics (PK) of drug molecules after pulmonary administration remains relatively poorly understood. Although plasma drug concentrations are commonly measured for estimating systemic drug exposure, the measurement of drug levels in the lung is not routinely carried out, typically because of the more difficult, labor-intensive sampling techniques and uncertainties in concentration determination methods. Consequently, there is no common standard in the sampling and measurement of lung PK.

In the literature, antibiotic concentrations in the lung have been measured in samples collected from bronchoalveolar lavage (BAL), sputum, microdialysis, and lung tissue homogenates.[@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18] However, these different sampling methods do not necessarily provide the same information. For instance, BAL and sputum samples are more likely to reflect extracellular drug concentrations, on the surface of the airways, whereas microdialysis samples are more likely to represent drug concentrations at a specific site of the lung parenchyma. In contrast, lung homogenates serve to provide a general estimation of total drug amounts in the lung and include both intracellular and extracellular drugs, with no indication of the specific site in the lung that was exposed to the drug delivery system. Although lung PK have been studied using one of these sampling approaches (i.e., BAL, sputum, lung homogenates, or microdialysis), to the best of our knowledge, few studies in the literature, if any, have collected and simultaneously analyzed drug concentrations in 3 sampling matrices (i.e., BAL, lung tissue homogenate, and plasma samples) from the same animals using a mathematical modeling approach to characterize the distribution of drugs between these physiological compartments.

In this study, we report the simultaneous modeling and analysis of drug concentrations in plasma and lung, with or without BAL sampling, of 3 prototype QSIs following pulmonary administration. SEN001 is a prototype QSI, which antagonizes the action of PqsR, a lysR-type regulator of the alkyl-quinolone (AQ)-dependent QS signaling system in PA, with promising *in vitro* activity.[@bib19] SEN019 and SEN032 are newly designed structural analogues of SEN001, which also antagonize PqsR and hence inhibit QS. These compounds were studied *in vivo* to investigate their therapeutic potential and suitability as drug candidates. The PK of the compound series following pulmonary administration was studied in rats, and the observed concentrations were simultaneously analyzed and modeled. The study demonstrated the use of pharmacometric modeling as a powerful tool to inform drug candidate selection in preclinical drug development of treatments for pulmonary delivery. During the analysis, a pharmacokinetic model was developed to describe all available observations from the compound series, and the estimated parameters provided quantitative insights into the distribution and clearance properties of the 3 QSI compounds. Furthermore, the model was able to quantify drug amounts in the lung before BAL collection, thus allowing direct comparison of local lung exposures between compounds, with or without BAL sampling. The developed model was then used to predict *in vivo* exposure following different dosing regimens to support the design of pharmacodynamics studies in disease models. The potential impact of systemic clearance on lung exposure to the drugs following pulmonary administration was also investigated.

Materials and Methods {#sec2}
=====================

Compounds {#sec2.1}
---------

SEN001 (3-amino-7-chloro-2-nonylquinazolin-4(3H)-one),[@bib19] SEN019, and SEN032 are PqsR antagonists developed at the University of Nottingham. SEN001 and SEN019 were synthesized in house, whereas SEN032 was purchased from Enamine Ltd (Kiev, Ukraine). The structure of SEN001 is shown in [Figure 1](#fig1){ref-type="fig"}. SEN019 and SEN032 are structural analogues of SEN001, and the sites of modification from SEN001 are indicated with small numbers in [Figure 1](#fig1){ref-type="fig"}. The structures of SEN019 and SEN032 are not disclosed for intellectual property protection purposes because the compounds are patent-pending. Polyethylene 400 (PEG400) and polysorbate 80 (PS80) were purchased from Sigma-Aldrich (Stockholm, Sweden).Figure 1The structure of SEN001 with the numbers indicating the site of modifications.

Compound Characterization {#sec2.2}
-------------------------

Measurements of melting point (T~m~) of the compounds were performed by differential scanning calorimetry (DSC) using a DSC Q2000 (TA instrument), which was calibrated for temperature and enthalpy using indium. The instrument was equipped with a refrigerated cooling system. T~m~ was determined using an amount of 1-3 mg in nonhermetic sealed aluminum pans. The compounds were scanned at a heating rate of 10°C/min under a continuously purged dry nitrogen atmosphere (50 mL/min). Additional physicochemical properties were obtained *in silico* using ADMET Predictor Version 7.2 (Simulation Plus, Inc., Lancaster, CA). Two-dimensional SDF files of SEN001, SEN019 and SEN032, were introduced into the software, which evaluated the structures to calculate physiochemical and biopharmaceutical properties at pH 7.4. The physicochemical properties of the compound series are summarized in [Table 1](#tbl1){ref-type="table"}.Table 1The Physicochemical Properties of SEN001, SEN019, and SEN032CompoundMWp*K*aLog *P*HBDHBAT~m~ (°C)ΔH (J/g)SEN001321.853.295.111379.7136.2SEN019369.811.822.3515176.597.4SEN032319.812.89; 1.542.9203113.1104.6[^1]

Solubility Determination {#sec2.3}
------------------------

The equilibrium solubility of the crystalline compounds in various media was determined by adding excess of the solid compounds (2-3 mg) to 1 mL (or equivalent proportion) of either water or PP2% (a mixture of PS80 2% w/w and PEG400 2% w/w in water). Samples were incubated at 37°C for \>24 h to allow dissolution. The supernatant was separated from the excess solid by centrifugation at 30,279 × *g* for at least 20 min (Heraeus Megafuge 8R Centrifuge with a MicroClick 24 × 2 mL rotor). The concentration of the compound in the supernatant was then determined by high-performance liquid chromatography with ultraviolet-detection (HPLC-UV).

Metabolic Stability {#sec2.4}
-------------------

Briefly, metabolic stability of the compounds was determined in 0.5 mg/mL human liver microsomes at a compound concentration of 1 μM in 100 mM KPO4 buffer, pH 7.4, in a total incubation volume of 500 μL. The reaction was initiated by addition of 1 mM NADPH. At various incubation times (i.e., 0, 5, 10, 20, 40, and 60 min), a sample was withdrawn from the incubation, and the reaction in the sample was terminated by addition of cold acetonitrile. The amount of parent compound remaining was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Pharmacokinetic Studies {#sec2.5}
-----------------------

The PK data of the compound series were collected from a number of studies in rats (male; Sprague-Dawley). The PK study of SEN001 was performed at Laval University in Quebec, Canada. The PK study of SEN019 and SEN032 was performed at XenoGesis (Nottingham, UK) and its animal research facility Saretius (Nottingham, UK). The study protocols were reviewed and approved by the respective animal ethics committee at Laval University and Saretius. The animals were carefully monitored throughout the studies for signs of toxicity.

The drugs were given via intratracheal (IT) administration to the lungs. Briefly, for SEN001, rats were lightly anesthetized with gaseous isoflurane and placed in a supine position on a restraining board angled at approximately 60° to 70° from the horizontal. The tongue of the rat was gently pulled outward using forceps, Q-tips, and the blade of a small animal otoscope (Hallowel EMC, Pittsfield, MA) was positioned in the distal part of the mouth to enable visualization of the vocal cords. An adapted 2 inches 16G intravenous catheter was then maneuvered past the vocal cords to the trachea-bronchus bifurcation. A 250 μL aliquot of the dosing solution was then administered into the lungs. Following IT administration, the rats were returned to metabolic cages where they rapidly recovered from the isoflurane anesthesia. The study of SEN019 and SEN032 was performed based on a similar protocol. The animals were administered SEN001, SEN019, and SEN032 at doses of 0.067 mg/kg, 0.12 mg/kg, and 0.28 mg/kg of body weight, respectively. The selection of doses was restricted by the aqueous solubility and availability of the compounds at the time. Blood, lung, and BAL samples were collected at predetermined time points, and the samples were analyzed by LC-MS. A summary of the PK study design is shown in [Table 2](#tbl2){ref-type="table"}.Table 2Summary of the Design of the Pharmacokinetic StudiesCompound*N*Dose (mg/kg)Time Points (h)SamplingSEN001210.0670.5, 2, 4, 8, 12, 24, 48Plasma, lung and BALSEN019180.120.167, 0.5, 1, 3, 6, 24Plasma and lungSEN032180.280.167, 0.5, 1, 3, 6, 24Plasma and lung[^2]

Analytical Methods {#sec2.6}
------------------

For the solubility studies, the concentrations of the compounds in the samples were analyzed using an Agilent 1290 HPLC system (Agilent Technologies, Santa Clara, CA) equipped with a UV/Vis spectrometer DAD detector. The compounds were separated using an Agilent ZORBAX Eclipse XDB-C18, 3.5 μm, 4.6 × 100 mm. The column temperature was set to 50°C with a total run time of 4 (SEN019, SEN032) or 7 min (SEN001). The mobile phase was 80% v/v acetonitrile and 20% v/v water (SEN001, SEN032) or 70% v/v acetonitrile and 30% v/v water (SEN019), and the flow rate was 1 mL/min using an isocratic method. Absorbance of the compounds was monitored at 280 nm. The injection volume was 20 μL. Standard solutions were prepared by dissolving mixtures of the compounds in acetonitrile and analyzed with HPLC to prepare a calibration curve.

For the metabolic stability studies, the amount of parent compound remaining in the microsome samples was analyzed by LC-MS/MS. Briefly, quantitative analysis was performed using a Waters XEVO TQ mass spectrometer (MS) in positive electrospray MRM mode coupled to an Acquity ultraperformance liquid chromatography (UPLC) system. The MS ion transitions were SEN001 322/180.1, SEN019 370/111, and SEN032 320/140. The analytes were separated using a Waters BEH C18 2 × 50 mm column over a 2-min run time. The mobile phases were double-distilled water with formic acid (0.1%) and acetonitrile with formic acid (0.1%).

For the PK study of SEN001, the amounts of the drug in the samples were quantified by LC-MS. Briefly, the analyte was extracted from plasma and lung homogenate samples by solvent extraction with ethyl acetate. BAL samples were extracted by solid phase extraction (Waters Oasis MCX extraction cartridges). The quantitative analysis was conducted using a Shimadzu series 10AD VP LC system in tandem with an Applied Biosystems Qtrap 4000 hybrid triple-quadrupole linear ion trap mass spectrometer. The chromatographic separation was achieved using a Phenomenex Gemini C18 column (3.0 μm, 50 × 3.0 mm). The mobile phases were 0.1% (v/v) formic acid in water and methanol. The MS ion transition used for analyte detection was precursor ion \[M + H\]+ = 322.2 m/z, product ion \[M + H\]+ = 180.1 m/z.

For the PK study of SEN019 and SEN032, the amounts of drugs in the samples were quantified by LC-MS. Briefly, the plasma and lung samples were treated with acetonitrile for protein precipitation. Quantitative analysis was then performed using a Thermo TSQ Quantiva mass spectrometer in positive electrospray MRM mode coupled to a Thermo Vanquish UPLC system. MS ion transitions were SEN019 370/181 and 370/237, and SEN032 320/71 and 320/140. The analytes were separated using a Phenomenex, Kinetex, biphenyl 2.6μm, 50 × 2.1 mm column over a 1.3-min run time. The mobile phases were Milli-Q water with formic acid (0.1%) and acetonitrile with formic acid (0.1%).

Pharmacokinetic Model Development {#sec2.7}
---------------------------------

The data were first analyzed by noncompartmental analysis to obtain initial estimates. Model development was then performed in the nonlinear mixed-effects modeling software program NONMEM (version 7.3, ICON Development Solutions),[@bib20] with Perl-speaks-NONMEM (PsN),[@bib21] using the Laplacian conditional estimation method with interaction algorithm. R (R Foundation for Statistical Computing, Vienna, Austria) with the Xpose package[@bib22] was used for model evaluation and graphical analysis. Initially, models were independently developed for SEN001, SEN019, and SEN032 to obtain key disposition parameters. The observed concentrations were then combined to simultaneously analyze the pharmacokinetic profiles of the 3 drugs after IT administration.

The general structural model developed in the analysis is illustrated in [Figure 2](#fig2){ref-type="fig"}. Briefly, it consists of 1 central lung compartment (L) where lung homogenate and BAL samples were taken, 1 deep lung compartment (LP) to describe the disposition of drugs in the lung before systemic absorption, 1 central plasma compartment (C) where plasma samples were taken, and 1 peripheral tissue compartment (P) to describe the disposition of the drugs after systemic absorption. During the analysis, 1-, 2-, 3-, and 4-compartment disposition models were evaluated; the transfers of drug between these compartments over time (t) are shown in [(1)](#fd1){ref-type="disp-formula"}, [(2)](#fd2){ref-type="disp-formula"}, [(3)](#fd3){ref-type="disp-formula"}, [(4)](#fd4){ref-type="disp-formula"}, where *A* is the amount of drug in each compartment, and V, CL, and Q are the volume of distribution, clearance, and intercompartmental clearance parameters of the corresponding compartments, respectively.$$\frac{dA_{L}}{dt} = - \frac{CL_{LP}}{V_{L}} \cdot A_{L} + \frac{CL_{LP}}{V_{C}} \cdot A_{C} - \frac{Q_{L}}{V_{L}} \cdot A_{L} + \frac{Q_{L}}{V_{LP}} \cdot A_{LP}$$$$\frac{dA_{C}}{dt} = \frac{CL_{LP}}{V_{L}} \cdot A_{L} - \frac{CL_{LP}}{V_{C}} \cdot A_{C} - \frac{CL_{C}}{V_{C}} \cdot A_{C} - \frac{Q_{C}}{V_{C}} \cdot A_{C} + \frac{Q_{C}}{V_{P}} \cdot A_{P}$$$$\frac{dA_{P}}{dt} = \frac{Q_{C}}{V_{C}} \cdot A_{C} - \frac{Q_{C}}{V_{P}} \cdot A_{P}$$$$\frac{dA_{LP}}{dt} = \frac{Q_{L}}{V_{L}} \cdot A_{L} - \frac{Q_{L}}{V_{LP}} \cdot A_{LP}$$Figure 2Schematic diagram of the general structural model developed for the analysis. Abbreviations: BAL, bronchoalveolar lavage; CL~C~, central clearance; CL~LP~, clearance from lung to plasma; Q~C~, intercompartmental clearance between V~C~ and V~P~; Q~L~, intercompartmental clearance between V~L~ and V~LP~; V~C~, volume of the central plasma compartment; V~L~, volume of the central lung compartment; V~P~, volume of the peripheral tissue compartment; V~LP~, volume of the deep lung compartment.

Where BAL samples were available, the addition of a separate compartment for BAL concentrations was also evaluated but this was not included in the final model. In the final model, the total amount of drug in the central lung compartment represents the sum of drug amounts in the BAL and lung samples. The concentrations of drug in the BAL samples (C~BAL~) were quantified by estimating the fraction of drug collected in BAL (F~BAL~) from the amount of drug in the central lung compartment (A~L~) divided by the volume of fluid used to collect the BAL samples (V~BAL~) as shown in [Equation 5](#fd5){ref-type="disp-formula"}.$$C_{BAL} = \frac{F_{BAL}}{V_{BAL}} \cdot A_{L}$$

During the analysis, the general structural model was developed and applied to analyze the observed concentrations of the 3 compounds and the fit of various models with and without the different compartments was evaluated. The volume of the central lung compartment was fixed to the typical size of lungs in a rat (2 g) to maintain model identifiability. The model parameters were scaled to the typical weight of the rats (0.3 kg) for comparability.

Because the majority of samples were terminal samples, interindividual variability (IIV) of the pharmacokinetic parameters was not estimated. The estimation of both IIV and residual unexplained variability with good precision requires more than 1 sample per subject. For residual unexplained variability, a mixed proportional and additive error model and a proportional error model were evaluated. Although most observation types were sufficiently well described by the proportional error model, the plasma concentrations of SEN019 and SEN032 were better described by the mixed error model. Data below the lower limit of quantification (LLOQ) were handled using the likelihood-based M3 method.[@bib23]

The likelihood ratio test was used to evaluate statistical significance for inclusion of additional parameters in nested models, where the objective function value (OFV) is assumed to be χ^2^ distributed. A decrease in OFV of 3.84 between nested models with 1 parameter difference was considered to be a statistically significant difference at the 5% significance level. Model development was guided by the biological plausibility of the parameter estimates, the change in objective function value (∆OFV), parameter precision, and evaluation of diagnostic plots. The final model was evaluated by performing a visual predictive check (VPC). For the VPC, 1000 data sets were simulated from the final parameter estimates using the original data set as a template. The predicted medians and their corresponding 95% confidence intervals were computed from the simulation data and overlaid with the observed values.

Drug Exposure Prediction Study {#sec2.8}
------------------------------

To compare the potential exposure of lung and plasma to various doses of SEN001, SEN019, and SEN032 following pulmonary administration, the parameter estimates of the final pharmacokinetic model were used to perform a dosing simulation study. The mrgsolve package (version 0.8.12,; Metrum Research Group) in the software R was used to carry out the simulation. The mean dose in the PK studies, 0.15 mg/kg, was used to compute the predicted concentration-time profiles for a dose-normalized exposure comparison, and drug concentrations were predicted when the compounds were given every 24, 12, and 8 h.

To investigate the potential impact of systemic clearance on lung and systemic exposures to the drugs, predictions were generated from a virtual population composed of 1000 simulated data sets with variability in central clearance (CL~C~). Since physiological parameters are typically log-normally distributed, IIV was applied to CL~C~ using an exponential model, as shown in [Equation 6](#fd6){ref-type="disp-formula"}, where CL~i~ is the individual clearance, CL is the typical clearance of the population, and η is normally distributed with a coefficient of variance (CV) of 30% around mean 0.$$CL_{i} = CL \cdot e^{\eta}$$

Results {#sec3}
=======

Formulation Development {#sec3.1}
-----------------------

The solubility of SEN001, SEN019, and SEN032 in water and the PP2% formulation is shown in [Table 3](#tbl3){ref-type="table"}. The compounds had poor aqueous solubility and the measured equilibrium solubility values ranged from \<1 to 20.2 μg/mL. The PP2% formulation improved the solubility of the drugs significantly and increased the amount of solubilized drugs to \>180 μg/mL. In addition, PP2% did not cause any detectable acute toxicity to the lungs of the animals, as supported by histological examination of the terminal lung samples. PP2% was therefore used to deliver solubilized drugs for IT administration in the PK studies.Table 3Solubility (μg/mL) of SEN001, SEN019, and SEN032 in Water and the PP2% Formulation (Mean ± s.d., *n* = 3)MediumSEN001SEN019SEN032Water\<LLOQ20.2 ± 2.1315.1 ± 0.34PP2%230.6 ± 3.08182.7 ± 3.42395.8 ± 3.13[^3]

Metabolic Stability {#sec3.2}
-------------------

The metabolic stability results for SEN001, SEN019, and SEN032 in human liver microsomes are shown in [Table 4](#tbl4){ref-type="table"}. Overall, the results suggested that the metabolic stability of SEN001 was superior to that of SEN019 and SEN032. SEN019 and SEN032 were more likely to be rapidly cleared *in vivo* after systemic absorption as a result of extensive metabolism, as demonstrated by their high hepatic extraction ratios of 0.71 and 0.94, respectively.Table 4Metabolic Stability of SEN001, SEN019, and SEN032 in Human Liver MicrosomesCompoundHalf-Life (min)CL~int~ (mL/min)CL~H~ (mL/min)E~H~SEN00154.41491.7747.90.50SEN01922.03692.11066.70.71SEN0323.324,886.71414.70.94[^4]

Plasma Pharmacokinetics Following Pulmonary Administration {#sec3.3}
----------------------------------------------------------

Following pulmonary administration, SEN001, SEN019, and SEN032 were rapidly absorbed from lung to the plasma, as demonstrated by the rapid appearance of the drugs in plasma shortly after administration and the lack of a discernible absorption phase in the plasma concentration-time profiles ([Fig. 3](#fig3){ref-type="fig"}). After absorption from the lung, the plasma concentrations of SEN001 declined steadily over the sampling period. In contrast, the concentrations of SEN019 and SEN032 in plasma declined more rapidly and were below the LLOQ after 3 h and 6 h, respectively.Figure 3Visual predictive check of the final model showing the observed concentrations of SEN001, SEN019, and SEN032 in plasma, lung, and bronchoalveolar lavage (BAL) with the observed medians, 2.5th and 97.5th percentiles following intratracheal administration and the corresponding 95% confidence intervals of the predicted medians (shaded).

Lung Pharmacokinetics Following Pulmonary Administration {#sec3.4}
--------------------------------------------------------

The concentrations of SEN001 in lung and BAL declined more rapidly during the initial absorption and distribution into plasma and deep lung tissue. After reaching distribution equilibrium at 2 h, the decline in lung and BAL concentrations reflected the decline in plasma concentrations during the elimination phase. The lung and BAL concentrations were closely correlated throughout the sampling period. In contrast, the concentrations of SEN019 and SEN032 in the lung fell below the LLOQ after 1 h.

Pharmacokinetic Modeling {#sec3.5}
------------------------

The observed concentrations of the 3 drugs were all well described by the model with good predictive performance as demonstrated in the VPC ([Fig. 3](#fig3){ref-type="fig"}). Although the deep lung compartment (V~LP~) was needed to describe the observed concentrations for SEN001, the addition of a peripheral compartment (V~P~) did not result in statistically significant improvement in the model fit (∆OFV = −0.643). Neither the peripheral compartment (V~P~) nor the deep lung compartment (V~LP~) was needed to describe the observed concentrations for SEN019. In contrast, the four-compartment disposition model best described the observed concentrations for SEN032. The full model resulted in a statistically significant improved model fit compared to the reduced models without either the peripheral compartment (V~P~) or the deep lung compartment (V~LP~) (∆OFV = −9.054 and −10.47, respectively).

The final model described the drug concentration-time profiles of the plasma, lung, and BAL samples, allowing direct comparison of pharmacokinetic properties between the compounds with and without BAL sampling. During model development, an additional compartment was evaluated for the BAL samples, but this did not reflect the drug disposition kinetics. In contrast, the observed concentrations in the lung and BAL samples were best described when the amounts of drug in the 2 samples were combined in the central lung compartment and F~BAL~ was estimated. The parameter estimates of the final model and the relative standard errors are summarized in [Table 5](#tbl5){ref-type="table"}.Table 5Parameter Estimates and Relative Standard Errors of the Final ModelParameter[a](#tbl5fna){ref-type="table-fn"}Unit[b](#tbl5fnb){ref-type="table-fn"}DescriptionSEN001% RSESEN019% RSESEN032% RSECL~LP~L/hClearance--lung to plasma0.017570.072410.15010V~L~LVolume of distribution--central lung0.002--0.002--0.002--CL~C~L/hClearance--central0.0745101.1153.746V~C~LVolume of distribution--central0.0855310.58351.5112Q~C~L/hIntercompartmental clearance--central--------2.3525V~P~LVolume of distribution--peripheral--------1.3635Q~L~L/hIntercompartmental clearance--lung0.0059637----0.010717V~LP~LVolume of distribution--deep lung0.058219----0.0036015F~BAL~%Fraction in BAL0.9800.3--------PROP~PL~%Proportional error--plasma45.91224.8725.315ADD~PL~μg/LAdditive error--plasma----0.284220.50542PROP~LG~%Proportional error--lung43.51318.12546.130PROP~BAL~%Proportional error--BAL38.022--------[^5][^6][^7]

Predicted Lung and Plasma Exposure Following Different Dosing Regimens {#sec3.6}
----------------------------------------------------------------------

The concentrations of SEN001 in the lung before BAL collection were calculated from the model, and a dose-normalized exposure comparison was performed using the predicted concentrations in lung and plasma following IT administration of the 3 compounds every 24, 12, and 8 h ([Figs. 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). The predicted profiles indicated that the concentrations of SEN001 in lung before BAL collection were much higher than those of the other 2 compounds. In contrast, SEN019 and SEN032 were rapidly cleared from both lung and plasma with minimal exposure following the different dosing regimens. The predicted lung and plasma exposure to SEN019 and SEN032 remained much lower than that to SEN001 administered every 24 h, even after more frequent dosing (up to every 12 and 8 h) and with variability in systemic clearance being taken into account, as demonstrated by the substantially lower area under the concentration-time curve (AUC) ([Fig. 6](#fig6){ref-type="fig"}). In addition, the impact of systemic clearance on lung concentrations appeared to be limited. Although the variability in plasma AUC resulting from the variability in central clearance ranged from 28.6% to 31.6%, the variability in lung AUC resulting from the same variability in central clearance ranged from only 1.2% to 5.3%.Figure 4The predicted drug concentration versus time profiles in lung showing the predicted median concentrations (line) and the corresponding 95% prediction intervals (shaded) computed from the 1000 data sets in the simulated population with variability (CV of 30%) in central clearance (CL~C~) following intratracheal administration of SEN001, SEN019, and SEN032 at 0.15 mg/kg every 24, 12, and 8 h (TAU).Figure 5The predicted drug concentration versus time profiles in plasma showing the predicted median concentrations (line) and the corresponding 95% prediction intervals (shaded) computed from the 1000 data sets in the simulated population with variability (CV of 30%) in central clearance (CL~C~) following intratracheal administration of SEN001, SEN019, and SEN032 at 0.15 mg/kg every 24, 12, and 8 h (TAU).Figure 6The area under the concentration-time curve (AUC) over 24 h computed from the predicted lung (top) and plasma (bottom) concentration-time profiles of the 1000 data sets in the simulated population \[means ± s.d.\] following intratracheal administration of SEN001, SEN019, and SEN032 at 0.15 mg/kg every 24, 12, and 8 h (TAU).

Discussion {#sec4}
==========

This study set out to investigate the pharmacokinetic properties of 3 prototype QSIs, SEN001, SEN019, and SEN032, being developed for the treatment of chronic PA lung infections, by collectively analyzing the observed concentrations from the PK studies. Because high local concentrations are desirable for treating lung infections, we focused on comparing drug concentrations in the lung following pulmonary administration. To remove the effect of dissolution, a solution was selected as the formulation of choice. Given the poor aqueous solubility of SEN001, chemical modifications were made to reduce the lipophilicity of this compound. The resulting SEN019 and SEN032 had, despite the lower logP, only moderately improved aqueous solubility. Hence, we developed a pulmonary formulation that effectively solubilized the compounds, using excipients that have previously been used in the lung.[@bib24], [@bib25], [@bib26] Being the most soluble compound in water in the series, SEN019 appeared to interact least with the solubilizing agents and was the least soluble compound of the 3 in the formulation. Nevertheless, this PP2% formulation significantly enhanced the solubility of the compounds, allowing administration of the drugs in solution via the pulmonary route. Consequently, drug dissolution and particle clearance from the lung (e.g., mucociliary clearance) were not considered in the model.

The pharmacokinetic properties of the compounds following IT administration were then investigated in rats. In the first PK study, SEN001 was administered and drug concentrations in plasma, lung, and BAL were evaluated. It was apparent that the drug was rapidly absorbed from the lung, as demonstrated by its early appearance in plasma. The large surface area and very thin alveolar epithelial lining of the lung have long been suggested to allow rapid systemic absorption.[@bib27], [@bib28], [@bib29] In fact, rapid systemic absorption from the lung, with peak plasma concentrations reached in 5 min, has also been observed after IT administration of other drugs.[@bib15], [@bib30], [@bib31], [@bib32] The plasma concentration-time profile of SEN001 was consistent with the rapid absorption previously reported following effective pulmonary delivery.

The decline of SEN001 concentrations in the lung homogenate and BAL samples mirrored its decline in the plasma samples after distribution equilibrium at 2 h. The concentrations of SEN001 in the lung and BAL samples were closely correlated throughout the whole sampling period, suggesting colocation of the drug sampled from the BAL and lung homogenate, with no kinetically discernible distribution phase. The pharmacokinetic model strengthened this hypothesis, since the addition of a separate distribution compartment for drug amount in BAL did not improve the characterization of the data. In contrast, the observed concentrations were well described when the amounts of the drug in lung and BAL were considered in the same compartment, and the distribution of drugs into plasma and deep lung was dependent on the total amount of drug in the central lung compartment. The fraction of the drug that remained in the airway was then collected in BAL from the central lung. Consequently, the model allowed quantification of the drug amount in the lung before BAL collection, and hence the direct comparison of lung exposures to other compounds without BAL sampling.

Lung PK are typically investigated by collecting either lung homogenates from small animals for total lung exposures, fluids from the airways (e.g., BAL or sputum) as an indication of the amount of drug in the epithelial lining fluid, or microdialysis for drug concentrations at a specific site in the lung.[@bib13], [@bib15], [@bib16], [@bib31], [@bib32], [@bib33], [@bib34] While total lung concentrations provide an estimate of overall lung exposure, they might not always represent the most relevant therapeutic exposure, since the amounts of intracellular and extracellular drugs are indistinguishable from each other. Depending on the location of the drug target, either intracellular or extracellular concentrations are likely to be more applicable. Although BAL sampling is subject to potential contamination with intracellular drugs released from cells that rupture before or during the procedure, it can serve to provide an initial indication of the amount of extracellular drug concentration.

Although drug transfer between BAL and plasma has been previously described using a modeling approach for the study of other antibiotics and antituberculosis drugs,[@bib15], [@bib35], [@bib36], [@bib37] few studies in the literature have simultaneously modeled and analyzed observed drug concentration-time profiles of plasma, BAL, and lung homogenate samples collected from the same animals using a quantitative approach. The results in the present study demonstrate the close relationship between SEN001 concentrations in BAL and the lung. The estimated fraction of SEN001 in BAL (F~BAL~) suggested that most (\>98%) of the SEN001 in the lung was likely residing on the epithelial lining of the airways, instead of being sequestrated intracellularly, before systemic absorption.

SEN019 and SEN032 were developed as structural analogues of SEN001. Given the lack of a discernible distribution phase between BAL and lung parenchyma for SEN001, BAL samples were not collected for SEN019 and SEN032. The concentrations of these 2 compounds appeared to decline more rapidly than those of SEN001. In addition, the LLOQs for SEN019 and SEN032 in the lung samples were different from that for SEN001, making direct comparisons of drug concentration-time profiles difficult. A pharmacokinetic model was therefore developed, using all of the observed concentrations available, for the characterization and comparison of the compound series.

The model described all of the concentration-time profiles of the compound series following pulmonary administration, allowing direct comparison of pharmacokinetic parameters between compounds. Although all 3 compounds appeared in plasma shortly after IT administration, SEN001 had the most favorable pharmacokinetic properties for targeted treatment in the lung, with the longest residence time in the lung after pulmonary administration, as demonstrated by the slowest clearance from lung to plasma (CL~LP~) and the additional deep lung compartment (V~LP~) in the model. In contrast, the estimated CL~LP~ of SEN032 was 107% and 757% higher than that of SEN019 and SEN001, respectively. It seems likely that SEN001, with the highest logP, distributed most widely into deep lung tissue, resulting in the slowest clearance to plasma and the longest residence time in the lung. Conversely, SEN019, with the lowest logP, did not distribute extensively after delivery, as illustrated by the lack of deep lung and peripheral compartment in the model, resulting in rapid elimination of the drug. In addition, SEN032 was also most rapidly cleared following systemic absorption, as shown by the highest central clearance (CL~C~). These results mirrored our findings on the metabolic stability of the compounds.

At first glance, the peak lung concentrations of SEN001 appeared much lower than those of SEN019 and SEN032. However, the SEN019 and SEN032 lung samples were analyzed directly, without BAL sampling. To compare concentrations in lung and plasma under standardized conditions, the model was used to perform a dose-normalized exposure analysis, by comparing the predicted drug concentrations in the lung and plasma following pulmonary administration of the same dose every 24, 12, and 8 h. Because the model allowed the estimation of lung concentrations before BAL sampling, direct comparison of lung concentrations between the compounds was possible. The results showed that SEN001 would reach much higher local concentrations in the lung after pulmonary administration compared to SEN019 and SEN032 ([Figs. 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). Even after multiple dosing up to every 8 h, it was unlikely that the lung and plasma exposures to SEN019 and SEN032 would be similar to SEN001 given every 24 h, as demonstrated by the much lower predicted exposures (AUC) from the simulated profiles ([Fig. 6](#fig6){ref-type="fig"}).

Although it is intuitive that physiological processes in the lung (e.g., mucociliary clearance and absorption from the lung) could impact on drugs available locally to treat lung infections, it is difficult to directly evaluate the influence of systemic clearance on local drug exposure in the lung following pulmonary delivery. Hence, drug exposures were predicted using the model with variability in the central clearance (CL~C~) parameter to investigate the specific impact of systemic clearance on lung concentrations of the compounds. The results showed that systemic clearance was unlikely to be the major factor impacting local drug exposure in the lung. It is therefore unlikely that the low SEN019 and SEN032 exposures could be improved by reducing systemic clearance. In contrast, lower systemic clearance could lead to a much more influential increase in systemic drug exposure and therefore an increased risk of systemic adverse effects. We therefore suggest that novel QSIs designed for direct delivery to the lung for targeted treatment of respiratory conditions should ideally have long residence times in the lung for maximum local exposure and efficacy with rapid clearance after systemic absorption to reduce the risk of unwanted systemic adverse effects. This design strategy is consistent with the approach advocated for other local inhaled therapies such as inhaled corticosteroids,[@bib38], [@bib39], [@bib40] and the present study provides further quantitative insights into the underlying drug dispositions resulting from such a delivery strategy using a mathematical modeling approach. Similar design principles should also be considered for local antimicrobial therapies.

Although it is certainly of relevance to understand the PK of newly synthesized compounds in healthy animals during the candidate selection process, it should be noted that the local airway conditions in CF lungs with chronic PA infection are quite different compared to the ones in healthy animals. The presence of thick and viscous mucus could potentially hinder the clearance of drugs from the airways and alter their local PK profiles. In addition, the barriers that biofilms present to drug penetration to the microorganisms could have implications on the local residence time required for efficacy. Nonetheless, the results of the present study provide invaluable insights into the potential exposure of these compounds following pulmonary delivery. To further explore their therapeutic potential, studies to investigate the *in vivo* efficacy of these compounds in a relevant disease model would be beneficial.

Conclusions {#sec5}
===========

This study has demonstrated a number of applications where pharmacometric modeling can be used as a powerful tool to inform drug development for pulmonary delivery in a preclinical setting, including the direct comparison of the pharmacokinetic properties of compounds to facilitate drug candidate selection, the prediction of *in vivo* exposure following different dosing regimens, and the identification of ideal pharmacokinetic properties to guide the future development of the treatment. This is one of the few studies reported in the literature in which drug concentration-time profiles of BAL, lung homogenate, and plasma samples were modeled and analyzed simultaneously to study lung PK. In addition, based on the predicted drug exposures, we suggest that novel QSIs designed for pulmonary delivery as targeted treatments for respiratory conditions should ideally have long residence times in the lung for local efficacy, with rapid clearance after systemic absorption to reduce the risk of unwanted systemic adverse effects. The developed model can also be connected to an infection model to study drug exposure-response relationships to improve the understanding of the pharmacokinetic-pharmacodynamic relationships of QSIs. Studies to develop QSIs as a novel treatment option for chronic PA lung infections are currently being undertaken.
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[^1]: HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; MW, molecular weight in g/mol; T~m~, onset melting temperature; ΔH, melting enthalpy.

[^2]: BAL, bronchoalveolar lavage; *N*, number of subjects.

[^3]: LLOQ, lower limit of quantification (1 μg/mL); PP2%, PEG400 2% + PS80 2% w/w in water.

[^4]: CL~int~, intrinsic clearance; Cl~H~, hepatic clearance; E~H~, hepatic extraction ratio.

[^5]: BAL, bronchoalveolar lavage; RSE, relative standard error.

[^6]: CL and V are apparent pharmacokinetic parameters following intratracheal administration and additive errors are expressed as variance.

[^7]: Parameters are scaled to 0.3 kg (typical weight of rats).
